Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo may stop hepatitis c spread in organ transplants

NCT ID NCT04508907

Prevention Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a donor with hepatitis C. About 200 participants who are hepatitis C-negative will take the drugs soon after transplant. The goal is to see if this approach stops the virus from taking hold and improves survival of both the patient and the transplanted organ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection * Willing to accept and consent for accepting hepatitis C positive graft Exclusion criteria: * Existing chronic liver disease (liver cirrhosis) * Concomitant infection with HIV or Chronic hepatitis B * Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection * Pregnancy (Pregnant patients do not undergo solid organ transplants)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart transplant infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart transplant infection Hepatitis C Kidney transplant; complications

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Phoenix, Arizona, 85054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.